US 12,251,471 B2
Inhalable therapeutics
Jeonghwan Kim, Corvallis, OR (US); and Gaurav Sahay, Corvallis, OR (US)
Assigned to Oregon State University, Corvallis, OR (US)
Filed by Oregon State University, Corvallis, OR (US)
Filed on Jul. 25, 2022, as Appl. No. 17/872,830.
Claims priority of provisional application 63/225,766, filed on Jul. 26, 2021.
Prior Publication US 2023/0043677 A1, Feb. 9, 2023
Int. Cl. A61K 9/1272 (2025.01); A61K 9/00 (2006.01); A61K 31/7105 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 9/0078 (2013.01); A61K 31/7105 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A nanoparticle comprising:
from 30 mol % to 65 mol % of an ionizable lipid;
from 30 mol % to 60 mol % of β-sitosterol;
from 5 mol % to 20 mol % of a structural lipid; and
from 3.5 mol % to 4.5 mol % of a PEG lipid;
in amounts relative to each other.